6-benzyloxy-4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline | 516526-46-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-benzyloxy-4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline
• 英文别名: 4-[(6-benzyloxy-7-methoxy-4-quinolyl)oxy]-3-fluoro-nitrobenzene；4-(2-fluoro-4-nitrophenoxy)-7-methoxy-6-phenylmethoxyquinoline
• CAS: 516526-46-8
• 化学式: C₂₃H₁₇FN₂O₅
• 分子量: 420.397
• InChiKey: VAQPAAWKETXEQP-UHFFFAOYSA-N

物化性质

• 沸点：
  554.0±50.0 °C(Predicted)
• 密度：
  1.346±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  86.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-benzyloxy-4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline 在 吡啶 、 氢溴酸 、 potassium carbonate 、 氯化铵 、 溶剂黄146 、 锌 作用下， 以 二苯醚 、 乙醇 、 水 为溶剂， 反应 106.0h， 生成 2-{4-[2-fluoro-4-(2-trifluoromethylbenzenesulfonylamino)phenoxy]-6-methoxyquinolin-7-yloxy}-N,N-dimethylacetamide
  参考文献：
  名称：

  Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors

  摘要：

  The overexpression of AXL kinase has been described in many types of cancer. Due to its role in proliferation, survival, migration, and resistance, AXL represents a promising target in the treatment of the disease. In this study we present a novel compound family that successfully targets the AXL kinase. Through optimization and detailed SAR studies we developed low nanomolar inhibitors, and after further biological characterization we identified a potent AXL kinase inhibitor with favorable pharmacokinetic profile. The antitumor activity was determined in xenograft models, and the lead compounds reduced the tumor size by 40% with no observed toxicity as well as lung metastasis formation by 66% when compared to vehicle control.

  DOI：

  10.1021/acs.jmedchem.8b00672
• 作为产物：
  描述：

  氯化苄 在 aluminum (III) chloride potassium carbonate 作用下， 以 氯仿 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 7.0h， 以27%的产率得到6-benzyloxy-4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline
  参考文献：
  名称：

  EP1447405

  摘要：

  公开号：

文献信息

• Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
  申请人：Miwa Atsushi

  公开号：US20050049264A1

  公开（公告）日：2005-03-03

  An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; Q represents NR 10 , CR 11 R 2 , carbonyl, O, S(═O)m, wherein m is 0 to 2, or urea; R 1 to R 3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R 4 represents H; R 5 to R 8 each independently represent H, halogen, alkyl, or alkoxy; and R 9 represents an optionally substituted carbocyclic or heterocyclic group.

  本发明的目标是提供新型化合物，其具有对FGF受体家族自磷酸化的抑制活性，并在口服或静脉注射时能够抑制癌细胞的生长。本发明的化合物由公式（I）或其药学上可接受的盐或溶剂表示：其中X代表CH或N; Z代表O或S; Q代表NR10，CR11R2，羰基，O，S（═O）m，其中m为0到2，或脲基; R1至R3各自独立地表示H、OH、卤素、硝基、氨基、烷基、烷氧基或其类似物，其中烷基和烷氧基基团可选择性地被取代; R4表示H; R5至R8各自独立地表示H、卤素、烷基或烷氧基; R9表示一个可选择性取代的碳环或杂环基团。
• Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
  申请人：Miwa Atsushi

  公开号：US20080207617A1

  公开（公告）日：2008-08-28

  An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, OH, or optionally substituted alkoxy; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, Hal, alkyl or the like; and R 9 represents, e.g., alkyl substituted by t-butyl or the like.

  本发明的目标是提供化合物和药物，用于治疗抑制FMS样酪氨酸激酶3（Flt3）自磷酸化在治疗上具有疗效的疾病。本发明涉及一种药物组合物，用于治疗或预防抑制Flt3自磷酸化在治疗或预防上具有疗效的疾病，所述药物组合物包括以下公式（I）所表示的化合物或其药学上可接受的盐或溶剂：其中X代表CH或N；Z代表O或S；R1、R2和R3代表H、OH或可选取代的烷氧基；R4代表H；R5、R6、R7和R8代表H、卤素、烷基或类似物；R9代表例如被t-丁基或类似物取代的烷基。
• QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1447405A1

  公开（公告）日：2004-08-18

  An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents 0 or S; Q represents NR10, CR11R12, carbonyl, O, S(=O)m, wherein m is 0 to 2, or urea; R1 to R3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R4 represents H; R5 to R8 each independently represent H, halogen, alkyl, or alkoxy; and R9 represents an optionally substituted carbocyclic or heterocyclic group.

  本发明的目的是提供对 FGF 受体家族的自身磷酸化具有抑制活性的新型化合物，口服或静脉注射后可抑制癌细胞的生长。本发明的化合物由式（I）或其药学上可接受的盐或溶液表示： 其中 X 代表 CH 或 N；Z 代表 0 或 S；Q 代表 NR10、CR11R12、羰基、O、S(＝O)m（其中 m 为 0 至 2）或脲；R1 至 R3 各自独立地代表 H、OH、卤素、硝基、氨基、烷基、烷氧基或类似基团，其中烷基和烷氧基是任选取代的；R4 代表 H；R5 至 R8 各自独立地代表 H、卤素、烷基或烷氧基；R9 代表任选取代的碳环或杂环基团。
• QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1566379A1

  公开（公告）日：2005-08-24

  An objective of the present invention is to provide compounds and pharmaceticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R1, R2, and R3 represent H, OH, or optionally substituted alkoxy; R4 represents H; R5, R6, R7, and R8 represent H, Hal, alkyl or the like; and R9 represents, e.g., alkyl substituted by t-butyl or the like.

  本发明的目的是提供用于治疗抑制FMS样酪氨酸激酶3(Flt3)的自身磷酸化具有治疗效果的疾病的化合物和药剂。本发明涉及一种用于治疗或预防抑制 Flt3 自身磷酸化具有治疗或预防效果的疾病的药物组合物，该药物组合物包含由式（I）代表的化合物或其药学上可接受的盐或溶液： 其中 X 代表 CH 或 N；Z 代表 O 或 S；R1、R2 和 R3 代表 H、OH 或任选取代的烷氧基；R4 代表 H；R5、R6、R7 和 R8 代表 H、Hal、烷基或类似物；以及 R9 代表例如被叔丁基或类似物取代的烷基。
• EP1566379
  申请人：——

  公开号：——

  公开（公告）日：——